Primary lysis of eosinophils in severe desquamative asthma

Clinical and Experimental Allergy

Volumn 44, Issue 2, 2014, Pages 173-183

  Persson, C ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA; EOSINOPHIL CATIONIC PROTEIN;

APOPTOSIS; ASTHMA; BLOOD LEVEL; BRONCHUS MUCOSA; CELL GRANULE; DESQUAMATION; DESQUAMATIVE ASTHMA; DISEASE SEVERITY; EOSINOPHIL; FREE EOSINOPHIL GRANULE; HUMAN; LYSIS; NECROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPUTUM LEVEL; TISSUE INJURY; TISSUE LEVEL; TISSUE REPAIR;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; EOSINOPHILS; HUMANS; INTERLEUKIN-15; RESPIRATORY MUCOSA; SECRETORY VESICLES; SPUTUM;

EID: 84892757972     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12255     Document Type: Review

References (92)

1. Persson CG, Erjefalt JS. "Ultimate activation" of eosinophils in vivo: lysis and release of clusters of free eosinophil granules (Cfegs). Thorax 1997; 52:569-74.
2. Uller L, Andersson M, Greiff L et al. Occurrence of apoptosis, secondary necrosis, and cytolysis in eosinophilic nasal polyps. Am J Respir Crit Care Med 2004; 170:742-7.
3. Erjefalt JS, Greiff L, Andersson M et al. Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways. Am J Respir Crit Care Med 1999; 160:304-12.
4. Gleich GJ, Motojima S, Frigas E et al. The eosinophilic leukocyte and the pathology of fatal bronchial asthma: evidence for pathologic heterogeneity. J Allergy Clin Immunol 1987; 80(3 Pt 2):412-5.
5. Egesten A, Alumets J, von Mecklenburg C et al. Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique. J Histochem Cytochem 1986; 34:1399-403.
6. Filley WV, Holley KE, Kephart GM et al. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982; 2:11-6.
7. Gonzalez EB, Swedo JL, Rajaraman S et al. Ultrastructural and immunohistochemical evidence for release of eosinophilic granules in vivo: cytotoxic potential in chronic eosinophilic pneumonia. J Allergy Clin Immunol 1987; 79:755-62.
8. Volbeda F, Broekema M, Lodewijk ME et al. Clinical control of asthma associates with measures of airway inflammation. Thorax 2013; 68:19-24.
9. Torpier G, Colombel JF, Mathieu-Chandelier C et al. Eosinophilic gastroenteritis: ultrastructural evidence for a selective release of eosinophil major basic protein. Clin Exp Immunol 1988; 74:404-8.
10. Gleich GJ, Flavahan NA, Fujisawa T et al. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol 1988; 81(5 Pt 1):776-81.
11. Motojima S, Frigas E, Loegering DA et al. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989; 139:801-5.
12. Persson CG, Erjefalt JS, Korsgren M et al. The mouse trap. Trends Pharmacol Sci 1997; 18:465-7.
13. Green DR, Victor B. The pantheon of the fallen: why are there so many forms of cell death? Trends Cell Biol 2012; 22:555-6.
14. Blakey JD, Wardlaw AJ. What is severe asthma? Clin Exp Allergy 2012; 42:617-24.
15. Persson C. Primary lysis/necrosis of eosinophils and clinical control of asthma. Thorax 2013; 68:295.
16. Fattahi F, Volbeda F, Broekema M et al. Authors' response to Persson C: primary lysis/necrosis of eosinophils and clinical control of asthma. Thorax 2013; 68:295-6.
17. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8.
18. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172:149-60.
19. Jeffery PK, Godfrey RW, Adelroth E et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 1:890-9.
20. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130(647-54):e10.
21. Persson C, Uller L. Transepithelial exit of leucocytes: inflicting, reflecting or resolving airway inflammation? Thorax 2010; 65:1111-5.
22. Flood-Page PT, Menzies-Gow AN, Kay AB et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
23. Desai D, Newby C, Symon FA et al. Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Severe Asthmatics. Am J Respir Crit Care Med 2013; 188:657-63.
24. Persson C. Primary lysis of eosinophils in severe obese asthma. Am J Respir Crit Care Med 2013; 188:1468.
25. Pizzichini MM, Pizzichini E, Clelland L et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med 1997; 155:1501-8.
26. Erjefalt JS, Persson CG. New aspects of degranulation and fates of airway mucosal eosinophils. Am J Respir Crit Care Med 2000; 161:2074-85.
27. Muniz-Junqueira MI, Barbosa-Marques SM, Junqueira LF Jr. Morphological changes in eosinophils are reliable markers of the severity of an acute asthma exacerbation in children. Allergy 2013; 68:911-20.
28. Kulkarni NS, Hollins F, Sutcliffe A et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol 2010; 126(61-9):e3.
29. Salvato G. Quantitative and morphological analysis of the vascular bed in bronchial biopsy specimens from asthmatic and non-asthmatic subjects. Thorax 2001; 56:902-6.
30. Pizzichini E, Pizzichini MM, Efthimiadis A et al. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997; 99:539-44.
31. Koh GC, Shek LP, Goh DY et al. Eosinophil cationic protein: is it useful in asthma? A systematic review Respir Med 2007; 101:696-705.
32. Malm-Erjefalt M, Greiff L, Ankerst J et al. Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy 2005; 35:1334-40.
33. Green RH, Pavord I. Stability of inflammatory phenotypes in asthma. Thorax 2012; 67:665-7.
34. Kano G, Almanan M, Bochner BS et al. Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol 2013; 132:437-45.
35. Persson C, Uller L. Transepithelial exit of leucocytes: inflicting, reflecting or resolving airway inflammation? Thorax 2011; 65:1111-5.
36. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
37. Tarodo de la Fuente P, Romagnoli M, Carlsson L et al. Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma. Respir Med 1999; 93:183-9.
38. ten Brinke A, Zwinderman AH, Sterk PJ et al. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med 2004; 170:601-5.
39. Kita H, Abu-Ghazaleh R, Sanderson CJ et al. Effect of steroids on immunoglobulin-induced eosinophil degranulation. J Allergy Clin Immunol 1991; 87(1 Pt 1):70-7.
40. Gauvreau GM, Ellis AK, Denburg JA. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009; 39:1297-306.
41. Berair R, Pavord ID. Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma. Curr Allergy Asthma Rep 2013; 13:469-76.
42. Weiler CR, Kita H, Hukee M et al. Eosinophil viability during immunoglobulin-induced degranulation. J Leukoc Biol 1996; 60:493-501.
43. Erjefalt JS, Korsgren M, Nilsson MC et al. Association between inflammation and epithelial damage-restitution processes in allergic airways in vivo. Clin Exp Allergy 1997; 27:1344-55.
44. Greiff L, Erjefalt JS, Andersson M et al. Generation of clusters of free eosinophil granules (Cfegs) in seasonal allergic rhinitis. Allergy 1998; 53:200-3.
45. Woolley KL, Adelroth E, Woolley MJ et al. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med 1995; 151:1915-24.
46. Aalbers R, Kauffman HF, Vrugt B et al. Allergen-induced recruitment of inflammatory cells in lavage 3 and 24 h after challenge in allergic asthmatic lungs. Chest 1993; 103:1178-84.
47. Tateishi K, Motojima S, Kushima A et al. Comparison between allergen-induced and exercise-induced asthma with respect to the late asthmatic response, airway responsiveness, and Creola bodies in sputum. Ann Allergy Asthma Immunol 1996; 77:229-37.
48. Persson C, Uller L. Roles of plasma exudation in asthma and COPD. Clin Exp Allergy 2009; 39:1626-9.
49. Toyoda M, Maruyama T, Morohashi M et al. Free eosinophil granules in urticaria: a correlation with the duration of wheals. Am J Dermatopathol 1996; 18:49-57.
50. Knight DA, Holgate ST. The airway epithelium: structural and functional properties in health and disease. Respirology 2003; 8:432-46.
51. Erjefalt JS, Korsgren M, Nilsson MC et al. Prompt epithelial damage and restitution processes in allergen challenged guinea-pig trachea in vivo. Clin Exp Allergy 1997; 27:1458-70.
52. Naylor B. The shedding of the mucosa of the bronchial tree in asthma. Thorax 1962; 17:69-72.
53. Ogata H, Motojima S, Fukuda T, Makino S. [Creola bodies and the eosinophil cationic protein in sputum in acute asthmatic attacks with respect to their clinical significance] Arerugi 1990; 39:1567-75.
54. Louis RE, Cataldo D, Buckley MG et al. Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J 2002; 20:325-31.
55. Gibson PG, Simpson JL, Hankin R et al. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax 2003; 58:116-21.
56. Erjefalt JS, Erjefalt I, Sundler F et al. In vivo restitution of airway epithelium. Cell Tissue Res 1995; 281:305-16.
57. Persson CG, Erjefalt JS, Erjefalt I et al. Epithelial shedding-restitution as a causative process in airway inflammation. Clin Exp Allergy 1996; 26:746-55.
58. Erjefalt JS, Persson CG. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 1997; 52:1010-2.
59. Persson C, Andersson M, Uller L. Epithelial Repair and Function. Chichester: Wiley, 2008.
60. Louis R, Lau LC, Bron AO et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9-16.
61. Pizzichini MM, Pizzichini E, Clelland L et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999; 13:15-21.
62. Desai D, Gupta S, Siddiqui S et al. Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma. Respir Res 2013; 14:17.
63. Erjefält JS, Sundler F, Persson CGA. Structural changes in the airways after acute and repeated epithelial denudation in vivo. Am J Respir Crit Care Med 1995; 151:A698.
64. Kallos P, Kallos L. Experimental asthma in guinea pigs revisited. Int Arch Allergy Appl Immunol 1984; 73:77-85.
65. Persson CG. Con: mice are not a good model of human airway disease. Am J Respir Crit Care Med 2002; 166:6-7; discussion 8.
66. Jose PJ, Griffiths-Johnson DA, Collins PD et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994; 179:881-7.
67. Costello RW, Schofield BH, Kephart GM et al. Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. Am J Physiol 1997; 273(1 Pt 1):L93-103.
68. Erjefalt JS, Uller L, Malm-Erjefalt M et al. Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration. Thorax 2004; 59:136-43.
69. Harlin SL, Ansel DG, Lane SR et al. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J Allergy Clin Immunol 1988; 81(5 Pt 1):867-75.
70. Prince LR, Graham KJ, Connolly J et al. Staphylococcus aureus induces eosinophil cell death mediated by alpha-hemolysin. PLoS ONE 2013; 7:e31506.
71. Kowalski ML, Cieslak M, Perez-Novo CA et al. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy 2011; 66:32-8.
72. Ueki S, Melo RC, Ghiran I et al. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 2013; 121:2074-83.
73. Hasala H, Malm-Erjefalt M, Erjefalt J et al. Ketotifen induces primary necrosis of human eosinophils. J Ocul Pharmacol Ther 2005; 21:318-27.
74. Racz P, Tenner-Racz K, Buttner DW et al. Ultrastructural evidence for eosinophil-parasite adherence (EPA) reaction in human onchocercal lymphadenitis in the early period following diethylcarbamazine treatment. Tropenmed Parasitol 1982; 33:213-8.
75. Yoon J, Ponikau JU, Lawrence CB et al. Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b. J Immunol 2008; 181:2907-15.
76. Olszewska-Pazdrak B, Pazdrak K, Ogra PL et al. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. J Immunol 1998; 160:4889-95.
77. Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or folklore? Blood 2012; 119:1214-6.
78. Melo RC, Liu L, Xenakis JJ et al. Eosinophil-derived cytokines in health and disease: unraveling novel mechanisms of selective secretion. Allergy 2013; 68:274-84.
79. Neves JS, Weller PF. Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. Curr Opin Immunol 2009; 21:694-9.
80. Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol 2012; 125:477-82.
81. Galluzzi L, Vitale I, Abrams JM et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20.
82. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19:75-86.
83. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 2012; 38:209-23.
84. Robinson N, McComb S, Mulligan R et al. Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol 2012; 13:954-62.
85. Kaiser WJ, Upton JW, Mocarski ES. Viral modulation of programmed necrosis. Curr Opin Virol 2013; 3:296-306.
86. Ch'en IL, Tsau JS, Molkentin JD et al. Mechanisms of necroptosis in T cells. J Exp Med 2011; 208:633-41.
87. Leist M, Single B, Castoldi AF et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481-6.
88. Di Paolo NC, Doronin K, Baldwin LK, Papayannopoulou T, Shayakhmetov DM. The transcription factor IRF3 triggers "defensive suicide necrosis in response to viral and bacterial pathogens. Cell Reports 2013; 3:1840-6.
89. Persson C. Airway, apoptosis, and asthma. Clin Exp Allergy 2013; 43:1083-5.
90. Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discovery 2011; 10:712.
91. Uller L, Rydell-Tormanen K, Persson CG et al. Anti-Fas mAb-induced apoptosis and cytolysis of airway tissue eosinophils aggravates rather than resolves established inflammation. Respir Res 2005; 6:90.
92. Persson C, Uller L. Primary lysis of eosinophils as a major mode of activation of eosinophils in human diseased tissues. Nat Rev Immunol 2013; 13:902. doi:10.1038/nri3341-c1 [Epub ahead of print].